A Ph 3, Prospective, Open-Label, Multicenter Study of Lymphoseek-Identified Sentinel Lymph Nodes (SLNs) Relative to the Path Status of Non SLN in an Elective Neck Dissection in Cutaneous Head and Neck and Intraoral Squamous Cell Carcinoma

Trial Profile

A Ph 3, Prospective, Open-Label, Multicenter Study of Lymphoseek-Identified Sentinel Lymph Nodes (SLNs) Relative to the Path Status of Non SLN in an Elective Neck Dissection in Cutaneous Head and Neck and Intraoral Squamous Cell Carcinoma

Discontinued
Phase of Trial: Phase III

Latest Information Update: 16 Oct 2016

At a glance

  • Drugs Tc 99m tilmanocept (Primary)
  • Indications Head and neck cancer; Squamous cell cancer
  • Focus Diagnostic use; Registrational
  • Sponsors Navidea Biopharmaceuticals
  • Most Recent Events

    • 16 Oct 2016 According to a Norgine Biopharmaceuticals media release, data from this study were presented at the European Association of Nuclear Medicine (EANM) 2016.
    • 15 Apr 2015 Results of lymph node detection in oral cancer will be presented at the 2015 American Head & Neck Society Annual Meeting & Translational Research Meeting.
    • 25 Mar 2015 According to a Navidea Biopharmaceuticals media release, data from this study were presented at the 68th Annual Cancer Symposium of the Society of Surgical Oncology (SSO) meeting 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top